{"id":"abbv-706","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CSF1R inhibition depletes tumor-associated macrophages (TAMs) and suppresses their pro-tumoral functions, including immunosuppression and angiogenesis support. By reducing macrophage-mediated immune evasion, ABBV-706 aims to enhance anti-tumor immunity and improve efficacy when combined with checkpoint inhibitors or other immunotherapies.","oneSentence":"ABBV-706 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage proliferation and activation in the tumor microenvironment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:37.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (in combination with checkpoint inhibitors)"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07155174","phase":"PHASE2","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-25","conditions":"Small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07310277","phase":"","title":"Expanded Access to ABBV-706","status":"AVAILABLE","sponsor":"AbbVie","startDate":"","conditions":"Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT07365241","phase":"PHASE3","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-04-14","conditions":"Small Cell Lung Cancer","enrollment":531},{"nctId":"NCT05599984","phase":"PHASE1","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-12-05","conditions":"Advanced Solid Tumors","enrollment":288}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ABBV-706","genericName":"ABBV-706","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABBV-706 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage proliferation and activation in the tumor microenvironment. Used for Advanced solid tumors (in combination with checkpoint inhibitors), Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}